Nutriband Inc.
NASDAQ:NTRBBiotechnology
+$0.85 today
- Market cap
- $58.59M
- Beta
- 1.97
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.66
Volume 0.03M
Average 0.01M
NTRB Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Nutriband Inc.NASDAQ: NTRB
Net Receivables · Q1 FY2026 · quarter ended Apr 2026
Net receivables falls 97.2% from a year ago
Net receivables stood at $2.63K at the end of Q1 FY2026, down 97.2% from a year earlier and down 97.8% from the prior quarter. Over 3 fiscal years it compounded at +1.6% a year.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, down 1.5 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -97.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 118.4K USD
- Year-over-year change
- +60.3%
- 4-year CAGR
- +13.5%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-31 | 118.4K | +60.3% |
| FY2024 | 2025-01-31 | 73.85K | -50.3% |
| FY2023 | 2024-01-31 | 148.65K | +31.5% |
| FY2022 | 2023-01-31 | 113.05K | +58.4% |
| FY2021 | 2022-01-31 | 71.38K | — |
Net Receivables vs competitors
How NTRB compares with its peers on the latest reported figures
- NTRB's Apr 2026 net receivables of $2.63K is the 6th highest of the 9 companies compared; the peer median is $159.67K.
- Its year-over-year change of -97.2% is the lowest of 5, against a peer median of +25.7%.
- Net receivables amounts to 0.0% of total assets for NTRB, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $25.51M | +39.1% | +1.8% | 7.1% | |
| Mar 2026 | $994.61K | +12.2% | +97.7% | 5.3% | |
| Mar 2026 | $405K | — | -7.7% | 0.2% | |
| Mar 2026 | $302K | -52.7% | -41.1% | 0.2% | |
| Dec 2025 | $17.35K | +108.8% | -69.6% | 0.0% | |
| Apr 2026 | $2.63K | -97.2% | +1.6% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding NTRB) | $159.67K | +25.7% | -7.7% | 0.1% | |
Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Jan 2024 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.89M | 1.99M | 492.94K | 4.31M | 4.57M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 71.38K | 113.05K | 148.65K | 73.85K | 118.4K |
| Inventory | 131.65K | 229.34K | 168.61K | 212.04K | 117.99K |
| Other Current Assets | 0 | 0 | 0 | (546) | 0 |
| Total Current Assets | 5.47M | 2.69M | 1.02M | 4.79M | 4.99M |
| Property, Plant & Equipment (Net) | 998.34K | 960.49K | 806.3K | 695.06K | 639.26K |
| Goodwill | 5.35M | 5.02M | 5.02M | 1.72M | 1.72M |
| Intangible Assets | 926.91K | 780.43K | 667.28K | 261.09K | 200.43K |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | (63) | 0 |
| Total Non-current Assets | 7.27M | 6.76M | 6.5M | 2.68M | 2.56M |
| Total Assets | 12.74M | 9.46M | 7.52M | 7.47M | 7.55M |
| Account Payables | 0 | 0 | 680.13K | 698.82K | 502.65K |
| Short-term Debt | 14.12K | 19.74K | 127.18K | 128.14K | 161.32K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 106.27K | 162.9K | 157.5K | 155.88K | 120.3K |
| Other Current Liabilities | 639.54K | 534.68K | 0 | 0 | 0 |
| Total Current Liabilities | 779.26K | 748.61K | 999.09K | 982.85K | 784.28K |
| Long-term Debt | 101.12K | 100.5K | 79.83K | 58.21K | 35.86K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 101.12K | 134.77K | 79.83K | 58.21K | 84.17K |
| Total Liabilities | 880.38K | 883.39K | 1.08M | 1.04M | 868.45K |
| Common Stock | 9.16K | 7.83K | 8.86K | 11.08K | 12.16K |
| Retained Earnings | (18.01M) | (22.49M) | (27.98M) | (38.46M) | (46.69M) |
| Accumulated OCI | (304) | (304) | (304) | (304) | (304) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 11.86M | 8.57M | 6.44M | 6.43M | 6.68M |
| Total Debt | 134.57K | 185.81K | 241.29K | 186.35K | 245.49K |
| Net Debt | (4.76M) | (1.8M) | (251.66K) | (4.13M) | (4.33M) |
Nutriband Inc.
NASDAQ:NTRB
Intrinsic Alpha fair value
Locked
Current Price
$4.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.